Search - tctmd.com

Displaying 21 - 40 of 428

Sort: Relevancy | Date

News Daily News

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

L.A. McKeown

December 05, 2024

Sustained Benefit With Pascal TEER Device at 2 Years: CLASP IID and MiCLASP

Michael O'Riordan

December 05, 2024

News Daily News

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

Todd Neale

December 04, 2024

News Conference News PCR London Valves 2024

Reverse Remodeling and Higher Stroke Volume With TEER: TRILUMINATE

Michael O'Riordan

December 03, 2024

News Daily News

IVC Filter Lawsuits Expose Holes in FDA Oversight and Public Communication

L.A. McKeown

December 03, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2024

Shelley Wood

December 03, 2024

News Daily News

New Platelet Function, Genetic Testing Consensus Seeks to Fill Gaps—Again

Yael L. Maxwell

November 27, 2024

News Daily News

ZENITH: Novel Biologic Reduces Morbidity and Mortality in PAH

L.A. McKeown

November 26, 2024

News Conference News AHA 2024

Novel AI-Based, Noninvasive Sensor Can Accurately Measure PCWP in HFrEF

Yael L. Maxwell

November 25, 2024

News Daily News

Closing the Left Atrial Septal Pouch For Stroke Prevention Explored in Small Trial

Todd Neale

November 25, 2024

News Conference News PCR London Valves 2024

Live Valve Cases Safe, With Outcomes Comparable to Trials and Practice

Michael O'Riordan

November 25, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

Todd Neale

November 18, 2024

News Conference News AHA 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

Caitlin E. Cox

November 18, 2024

News Conference News AHA 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

Shelley Wood

November 18, 2024

News Conference News AHA 2024

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

Michael O'Riordan

November 17, 2024

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

News Conference News AHA 2024

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

Shelley Wood

November 16, 2024

News Conference News AHA 2024

First-line Catheter Ablation Works for Post-MI VT Suppression: VANISH2

Caitlin E. Cox

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

Advertisement

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

Sustained Benefit With Pascal TEER Device at 2 Years: CLASP IID and MiCLASP

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

Reverse Remodeling and Higher Stroke Volume With TEER: TRILUMINATE

IVC Filter Lawsuits Expose Holes in FDA Oversight and Public Communication

TCTMD’s Top 10 Most Popular Stories for November 2024

New Platelet Function, Genetic Testing Consensus Seeks to Fill Gaps—Again

ZENITH: Novel Biologic Reduces Morbidity and Mortality in PAH

Novel AI-Based, Noninvasive Sensor Can Accurately Measure PCWP in HFrEF

Closing the Left Atrial Septal Pouch For Stroke Prevention Explored in Small Trial

Live Valve Cases Safe, With Outcomes Comparable to Trials and Practice

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

First-line Catheter Ablation Works for Post-MI VT Suppression: VANISH2

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content